Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Steris 510(k)

This article was originally published in The Gray Sheet

Executive Summary

Sterilization firm Steris has submitted a 510(k) for a modified version of its System 1 liquid chemical sterilization system, company says Jan. 20. FDA cited Steris in a May 15, 2008, warning letter for selling a modified version of System 1 without appropriate 510(k) clearance. The original system was cleared in 1989, but Steris later modified the product, including changing the pump, connector design and software, FDA said. Steris will continue supporting the System 1 installed base by providing accessories, service and parts for at least two years

You may also be interested in...



Regulatory News In Brief

Stryker recall: Firm recalls 23 Navigation System II operating room surgical navigation systems with a faulty component that may result in the screen freezing, or the system updating at a slow rate or not responding at all, Stryker and FDA announced in November communications about the Class I recall. Navigation System II is a computer-aided surgery platform used in hip, knee, spine, neurological and ear, nose and throat procedures. Hospitals were advised to stop using the product, which Stryker is arranging to have repaired. All domestic units have been fixed, and there have been no reported injuries, the firm notes

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Quotable: Words Of Wisdom From Our Recent APAC Coverage

Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027045

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel